Second Bite of the Apple Veterinary Practice: How Rollover Equity Works in 2026 PE Deals

July 17, 2026

Veterinarian reviewing an acquisition offer for their practice

Second Bite of the Apple Veterinary Practice: How Rollover Equity Works in 2026 PE Deals

Key takeaways

The second bite of the apple means a future payout from rollover equity when the PE-backed platform that bought your practice sells again, typically 3 to 7 years after your initial close.
Rollover equity is not cash — it is illiquid minority ownership in the acquirer’s platform, and its real value depends on equity class, deal structure, and the platform’s ultimate exit valuation.
PE buyers typically ask for 10% to 40% rollover, with 20% being the most commonly cited target. When structured as a tax-deferred exchange, you pay capital gains only on the cash portion at closing, not on the amount you roll.
Rollover equity and earnouts are different instruments — rollover equity is an ownership stake with uncapped upside tied to the whole platform; an earnout is a contingent payment tied to your specific practice hitting defined targets.
The structural terms matter more than the percentage — equity class, tag-along rights, anti-dilution protections, and information rights determine what your rollover is actually worth if and when the platform exits.
A competitive process is the only way to see the full range of rollover structures available to your practice, because no two offers are identical and most buyers don’t advertise their best terms to a seller talking to them alone.

There’s a moment in certain deals I walk through with a vet where the mood in the room shifts. Not when we talk about the headline number — that gets its own kind of attention.

The shift happens a few minutes later, when we get to the rollover section of the term sheet and the buyer’s rep says something like: “This is where the real upside lives.”

The idea has a name that has made it into almost every PE acquisition conversation in veterinary medicine over the past several years: the second bite of the apple veterinary practice deal. You take the first bite — your cash at close.

Then you hold a minority ownership slice in the platform that bought you, and when that platform eventually sells or recapitalizes, you get the second bite.

I’ve walked enough vet owners through these conversations to know that the concept sounds straightforward and the reality is more complicated. The second bite can be meaningful.

It can also be an illiquid, subordinated, undisclosed-risk position that looks nothing like the rosy number the buyer sketched on a whiteboard. Which one you end up with depends almost entirely on terms most sellers don’t know to ask for.

This article is about those terms. If you’re a vet practice owner in 2026 evaluating an offer that includes rollover equity, or trying to decide how much weight to put on the promised second bite, this is what I’d want you to understand before you sign anything.

The short answer: The second bite of the apple in a veterinary practice sale is the future payout from rollover equity — a minority ownership stake you retain in the PE-backed platform when the platform exits, typically 3 to 7 years after your original close. The first bite is the cash you received at closing.

Whether the second bite is worth pursuing depends on the equity class, the platform’s trajectory, and a set of structural protections most direct-offer conversations never surface.

What rollover equity actually is in a veterinary practice sale

Rollover equity is the portion of the sale price you receive not as cash but as an ownership stake in the acquiring entity. Instead of a 100% cash close, the seller reinvests a percentage back into the buyer’s platform and holds that stake as a minority interest until the platform exits.

The mechanics work like this. A PE-backed buyer values your practice, sets a deal price, and offers to pay most of it in cash at close — but not all.

The remainder becomes your equity position in the platform. That position is recorded on the platform’s capitalization table, and when the platform eventually sells, your percentage of the exit proceeds flows back to you.

Recapitalization is the closely related concept. When a PE fund’s hold period matures and the fund needs to return capital to its investors, it sells the platform to another buyer, goes public, or brings in a co-investor in a restructure.

Each of those events is a potential liquidity moment for equity holders, including the vet sellers who rolled in at their original transaction.

The second bite of the apple is the colloquial term for that future moment. The first bite was the cash you received when you sold.

The second bite is the proceeds you receive when the platform exits and your minority stake converts to cash.

Per M&A advisory data compiled by Colonnade Advisors, PE buyers across sectors typically expect sellers to roll between 10% and 40% of the total deal value, with 20% being the most commonly cited target. In the healthcare space, including veterinary platforms, forced rollover ranges have been shifting toward the higher end of that range as sponsors prioritize keeping founder alignment strong.

A veterinarian seated at a table reviewing a written acquisition term sheet, looking down at the document, candid documentary style, natural light, slight off-center composition

How the second bite of the apple works in a veterinary practice PE deal — a realistic illustration

I want to walk through a concrete scenario because the concept is easier to evaluate against real numbers than in the abstract.

Say your practice carries $1.2 million in normalized EBITDA — what the practice earns in pure operating profit, before taxes and accounting choices — and the offer on the table prices it at $12 million (a 10x multiple, the multiplier buyers apply to EBITDA to set the price).

The buyer offers 80% cash at close and asks you to roll the remaining 20%.

Cash at close: $9.6 million
Rollover equity: $2.4 million, representing a minority ownership percentage in the platform

Four years later, the platform has grown through additional acquisitions. The sponsor brings in a new financial partner in a recapitalization, and the implied platform value at that transaction places your percentage stake at $6.5 million.

Your total proceeds across both events: $9.6 million plus $6.5 million = $16.1 million — materially more than you would have received in an all-cash deal at 10x.

That’s the best-case shape of the second bite. It’s real, it has happened in veterinary consolidator platforms, and it’s worth thinking about seriously.

Now the harder version. Same structure, but the platform struggled with integration debt and staff turnover in years two and three.

The recapitalization happens at a compressed multiple. The sponsor, sitting on preferred equity, gets made whole first.

What remains for common equity holders — the class most sellers roll into when they don’t negotiate otherwise — is a much smaller number.

In a downside case, the second bite can return less than the face value of the rollover amount. The position was illiquid for four years, and you couldn’t course-correct.

Both scenarios are real. The structure terms you negotiate before signing determine which outcome is more likely for your equity.

Rollover equity vs. earnout: the difference every vet seller needs to understand in 2026

These two instruments get conflated constantly in PE acquisition conversations, and the confusion costs sellers real money.

Rollover equity is an ownership stake in the broader platform. Its value rises and falls with everything the platform does — every new acquisition, every rate environment shift, every integration success or stumble across the network of practices.

Your percentage is locked in at signing, you hold it indefinitely until the platform exits, and your payout has no cap if the platform performs well. It also has no floor.

An earnout is a contingent payment tied specifically to your practice hitting defined performance targets — typically EBITDA or revenue figures — over a defined period after closing, usually 1 to 3 years. We cover how earnouts work in detail in our guide to veterinary practice earnouts and rollover equity.

The critical point here is that an earnout‘s upside is capped by the formula written into your agreement, and its risk is concentrated in your individual practice’s performance post-close. Rollover equity‘s risk and upside are both spread across the whole platform.

Feature	Rollover equity	Earnout
What it tracks	Entire platform’s exit valuation	Your practice’s specific EBITDA/revenue targets
Upside ceiling	None (uncapped with platform growth)	Capped by formula
Payout trigger	Platform exit or recapitalization	Time-based performance milestones
Liquidity	Illiquid until platform exit	Paid on schedule if targets hit
Typical duration	3 to 7 years (fund lifecycle)	1 to 3 years post-close
Tax treatment	Can be structured as tax-deferred	Generally taxed as ordinary income on receipt
Risk profile	Whole-platform success required	Your practice’s post-close performance

Neither structure is inherently better. The right answer for any given seller depends on how much you trust the platform’s ability to scale, how long you can afford to leave capital illiquid, and what terms the buyer agrees to.

The equity class problem: why 20% rollover isn’t always 20% value in 2026 deals

This is the section of the rollover conversation that most sellers miss, and it’s where deals that look equivalent on the headline percentage turn out to be drastically different in value.

Preferred equity vs. common equity — these are the two primary classes in most PE deal capital structures. The sponsor typically sits on preferred, which means it is paid first in any exit or distribution.

Preferred equity often carries a liquidation preference (a guaranteed minimum return before common equity sees anything) and sometimes a preferred return that accrues like interest on the invested capital.

Common equity sits below preferred in the distribution waterfall — the order in which proceeds flow to each class of equity holder. In a modest exit where the total proceeds cover the preferred holders but leave limited upside, common equity holders receive little or nothing.

When a PE buyer offers you rollover equity as common equity while the sponsor sits on preferred, what looks like a 20% stake in a $100 million platform can deliver far less than $20 million if the exit doesn’t clear the sponsor’s preferred return threshold with room to spare.

Per Holland & Knight’s February 2026 commentary on minority deals in healthcare PE, the structure of rollover in platform transactions has been shifting. Forced rollover amounts have increased from historically typical 20% toward 50% in some healthcare deals, while the equity class terms have become more consequential and more variable than ever.

A 25% rollover into pari passu preferred equity — the same class and priority as the sponsor — is a structurally different and generally more protective position than a 25% rollover into junior common.

Negotiating your rollover class is one of the most valuable things a seller can do before signing.

The structural terms that determine what your second bite is actually worth

Beyond equity class, there are four contractual protections that every vet seller should understand before agreeing to a rollover.

Tag-along rights. A tag-along right gives you, as a minority equity holder, the ability to participate in any sale of the sponsor’s majority stake on the same economic terms. Without this, the sponsor can exit partially — selling a portion of their stake to a new buyer at a strong valuation — while you remain locked into the platform with no liquidity and no path to the proceeds that event generated.

Tag-along should be a non-negotiable term in any rollover agreement.

Anti-dilution protections. PE-backed platforms grow through acquisitions, and those acquisitions often require new equity capital. Each new equity raise dilutes the percentage held by existing shareholders, including you.

Without anti-dilution provisions, your 20% stake can become 12% over four years of add-on activity without anyone notifying you that it happened. Anti-dilution either prevents dilution or gives you the right to participate in new raises to maintain your percentage.

Information rights. Your rollover equity is an investment in a private company. Without contractual information rights — regular financial reporting, access to audited statements, notice of material events — you are holding an illiquid position with no visibility into how the platform is performing.

Information rights should include at minimum quarterly financial summaries and annual audited statements.

Put and call provisions or a defined exit window. Drag-along provisions give the sponsor the right to compel you to sell alongside them in a full platform sale, which is generally in your interest because it guarantees you exit at the same time. But without any defined liquidity window — a put right (you can force the platform to buy out your stake after a defined period) or a call right (the platform can buy your stake at a defined formula) — your equity is illiquid indefinitely if the platform never reaches a clean exit.

The Colonnade Advisors rollover equity framework describes tag-along rights as among the most important structural terms in any rollover agreement, because they address the fundamental asymmetry between a majority sponsor and a minority seller.

Tax deferral: the structure that makes rollover equity more efficient in 2026

One of the genuine advantages of rollover equity — when the deal is structured correctly — is the ability to defer capital gains tax on the portion you roll.

In a standard 100% cash sale of a veterinary practice, the seller pays capital gains tax on the full gain in the year of closing. In a rollover equity structure, only the cash portion is taxable at close.

The portion rolled into the new entity is treated as a Section 721 exchange (if rolling into a partnership or LLC structure) or a Section 351 exchange (if rolling into a corporation). Under either treatment, no capital gains tax is due on the rolled portion at close.

The tax obligation defers until the second-bite liquidity event.

Per M&A advisory data from Colonnade Advisors’ analysis of middle-market PE transactions, in 2019, 88% of transactions utilizing rollover equity used a tax-deferred structure. The fraction has remained consistently high because the structure benefits both sides — the seller defers taxes, and the buyer gets founder alignment without the seller demanding a cash premium to cover an immediate tax hit.

The tax deferral has limits. The rollover structure must be documented properly by your CPA and M&A attorney.

And when the second-bite proceeds arrive, they are taxable in that year as capital gains. For sellers in high-income years, the timing of the second bite matters for planning.

The bottom line: with proper legal and tax structuring, rollover equity lets you take a first bite that is more tax-efficient than an all-cash sale, and defer the tax on the deferred portion until the second bite arrives.

A veterinarian and a sell-side advisor reviewing deal term sheets together at a table, looking down at the documents, candid documentary style, warm ambient light, papers spread out, professional but informal setting

The 2026 landscape: when the second bite becomes the biggest number in the room

The veterinary consolidation market in 2026 is at a specific moment in its PE cycle that makes rollover equity a more active conversation than it was three or four years ago.

Capstone Partners‘ April 2026 Pet Sector M&A Update reported 18 announced or completed veterinary sector transactions in YTD 2026, compared to 8 in the prior year period. The Vet & Health segment accounts for 9 of those deals.

Critically, Capstone notes that 66 PE-backed veterinary platforms were formed between 2019 and 2022 — putting a large cohort of platforms at or past the typical 4 to 5 year hold period that triggers harvest-mode activity. From 2023 through YTD 2026, sponsors have exited only 9 investments, with 5 of those being sponsor-to-sponsor transactions (one PE firm selling to another, rather than a full exit).

That backlog matters for rollover equity holders for two reasons.

First, the pressure for distributions from limited partners (the institutional investors backing PE funds) is building. Capstone anticipates a stronger pipeline of PE-backed assets coming to market in 2026 and 2027 as fund lifecycles mature and LP demand for liquidity intensifies.

More exits means more second-bite moments for vet sellers who rolled equity in the 2019 to 2022 wave.

Second, the sponsor-to-sponsor pattern means the second bite for many vets who rolled in that period will not be a public market exit (IPO) but another PE transaction, with another fund taking majority control. For rollover equity holders, a sponsor-to-sponsor exit can be a clean liquidity event — but only if the tag-along rights in the original agreement cover that type of transaction.

Mission Pet Health, the combined entity formed from the late 2024 merger of Southern Veterinary Partners and Mission Veterinary Partners, with the new unified brand launched July 2025, is among the most active platforms in the market today per public reporting. The merger itself represented a consolidation-level recapitalization.

PE sponsor Shore Capital Partners backs the combined entity.

Sellers who rolled equity at their original SVP or MVP practice sale had a potential liquidity event at the merger. How much value that event delivered to individual rollover holders depended entirely on the terms of their original rollover agreements — precisely the structural details this article covers.

What a competitive process reveals about rollover equity in 2026

Here’s the pattern I see consistently in the processes we run. Sellers who come to us after a direct conversation with one buyer often have a single data point on rollover terms: what that one buyer offered them.

They have no way to know whether the equity class is standard or subordinated, whether the rollover percentage is at the high or low end of the market, whether the tag-along language protects them fully or partially, or whether another platform’s offer carries a meaningfully different structure.

The Elite Selling System — our approach of hand-selecting and vetting every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then running a private competitive bidding window inside that vetted group — surfaces this information directly. When multiple qualified buyers submit competing offers for the same practice, the rollover terms across those offers become immediately comparable.

You see which buyers want 15% rollover and which want 35%. You see which are offering pari passu preferred and which are offering junior common.

You see which include strong tag-along provisions and which bury a narrow definition of qualifying transactions that leaves the protection nearly toothless.

None of that is visible in a single-buyer conversation. The competitive process is the instrument that makes rollover equity terms legible.

We cover the broader context of who the major PE-backed buyers are in the veterinary practice consolidators guide and how to think about which buyer type fits your practice in the who to sell your veterinary practice to guide. The deal structure question — including rollover — comes into focus most sharply once you know what the full buyer pool looks like and have multiple offers to compare.

What to do if you’re evaluating a rollover equity offer now

If you have a term sheet in front of you that includes rollover equity, the questions worth asking before you respond are concrete.

What equity class will my rollover position hold — preferred (pari passu with the sponsor) or common? What are the sponsor’s preferred return terms, and at what exit value does common equity begin to participate meaningfully?

Does the agreement include tag-along rights, and do those rights cover sponsor-to-sponsor transactions and partial sales? What anti-dilution protections exist if the platform raises additional equity?

Do I have information rights that give me regular financial visibility into the platform? Is there a defined exit window, put right, or call mechanism?

And: can the rollover portion be structured as a tax-deferred exchange?

No single one of these questions has a universally correct answer. A 30% rollover into pari passu preferred with full tag-along at a modestly valued platform can outperform a 15% rollover into junior common at a highly valued one if the exit environment normalizes.

The arithmetic depends on terms, not just percentages.

What I’d tell you across a dinner, the same way I’ve told it to owners at this decision point before: the second bite can be genuinely compelling. Don’t dismiss it.

But don’t accept the buyer’s framing of it at face value without reading the structure carefully. Get your M&A attorney to mark up the equity documents.

Have a CPA confirm the tax treatment before you sign. And if you haven’t run a competitive process, understand that the rollover terms on your one offer are one data point, not the market.

A veterinary practice valuation tells you what your practice is worth. A competitive process tells you what the best buyer in the market will pay — and on what terms.

For rollover equity specifically, those terms are where the difference between a compelling second bite and a disappointing one lives.

If you’re at the point of evaluating a PE offer that includes rollover equity, the most useful thing I can give you is a picture of where your practice’s total deal value sits across the range of buyers active in the market today — before you accept or reject any rollover structure.

You can get a free, confidential practice value estimate whenever it makes sense.

That estimate doesn’t commit you to anything. It gives you a reference point against which the rollover offer in front of you can be measured.

If the cash-at-close is already at the ceiling of what the competitive market would produce, rolling equity may be the only path to additional value. If the competitive market has meaningfully higher offers, the rollover question becomes secondary to closing the gap on the first bite.

We work on a success-based model — no upfront fees, compensated only when a deal closes and only out of value created above what you would have received on your own. Reach us through the link above and we can map your situation against current deal flow.

Frequently asked questions

What is the second bite of the apple in a veterinary practice sale?

The second bite of the apple refers to the future payout a vet practice owner receives from rollover equity when the acquiring PE-backed platform eventually sells, recapitalizes, or goes public. The first bite is the cash received at the initial closing.

The second bite is the proceeds from the minority ownership stake the seller held in the platform, typically realized 3 to 7 years after the original sale, if the platform succeeds and exits.

What is rollover equity in a veterinary practice PE deal?

Rollover equity is the portion of the sale price that a veterinary practice owner receives not as cash but as an ownership stake in the acquiring PE-backed entity. Instead of a 100% cash close, the seller reinvests a percentage back into the buyer’s platform.

PE buyers in veterinary practice acquisitions typically ask sellers to roll between 10% and 40% of their proceeds, with 20% being the most commonly cited target. The rollover stake remains illiquid until a future exit event.

How is rollover equity different from an earnout in a vet practice sale?

Rollover equity is an ownership stake in the acquiring entity that you hold until the platform exits. Its value rises or falls with the platform’s overall performance and exit valuation, and you have no guaranteed payout.

An earnout is a contingent payment tied to your specific practice hitting defined performance targets, typically EBITDA or revenue goals, over a set period after closing. Both structures defer a portion of your total consideration, but rollover equity‘s upside is uncapped while an earnout’s upside is capped at the agreed formula.

We cover earnouts separately in our rollover and earnout article.

What percentage rollover equity is typical in a veterinary practice PE deal in 2026?

PE buyers in veterinary practice acquisitions have historically asked sellers to roll between 10% and 40% of the total deal value, with 20% being the most commonly cited target across M&A advisory commentary. In some healthcare platform deals, forced rollover amounts have shifted toward the higher end of that range as sponsors seek to keep founder alignment strong.

The specific percentage in any one deal is negotiated case by case, and a competitive process with multiple qualified bidders is the only way to know where the range truly sits for your practice.

Is rollover equity taxable when I sell my veterinary practice?

When structured properly, rollover equity can be treated as a tax-deferred exchange under IRC Section 721 or Section 351. This means you pay capital gains tax only on the cash portion of the deal at closing, not on the portion you roll over.

The rolled portion becomes taxable only when the platform sells and you receive the second-bite proceeds. Per M&A advisory data, in 2019, 88% of transactions utilizing rollover equity used a tax-deferred structure.

Your CPA and M&A attorney need to confirm the tax treatment for your specific structure.

What are the biggest risks of rollover equity for veterinary practice sellers?

The four main risks are: (1) illiquidity — the stake cannot be sold until the platform exits, which may take 4 to 7 years or longer; (2) equity class subordination — if you roll into common equity while the sponsor sits on preferred, the sponsor is made whole first in any exit, which can leave little for common holders in a modest outcome; (3) dilution — add-on acquisitions and new capital raises can dilute your percentage without protections; and (4) platform dependency — your second-bite value depends on the overall platform’s performance, not just your original practice. Tag-along rights, anti-dilution protections, and information rights are the structural safeguards to negotiate.

What deal terms should I negotiate in a rollover equity offer for my veterinary practice?

The most important terms to negotiate are: (1) equity class — push for pari passu preferred (same class as the sponsor) rather than common equity that is subordinated in the distribution waterfall; (2) tag-along rights — the right to participate in any partial sale or recapitalization on the same terms as the sponsor; (3) anti-dilution protection — prevents your percentage from shrinking without your consent when the platform adds new capital; (4) information rights — regular financial reporting so you can monitor the platform’s health; and (5) put/call provisions or a defined exit window. These terms matter more than the headline rollover percentage.

Can the second bite of the apple be worth more than the first in a veterinary practice sale?

Yes, in a well-performing platform exit it can. A practice valued at $10 million might close with 70% cash ($7 million) and 30% rollover equity ($3 million of platform equity).

If the platform grows and exits at a blended value that places the seller’s 30% stake at $9 million or more, the second bite exceeds the initial rollover amount. But this depends entirely on the platform’s exit valuation, the equity class held, and the structure terms negotiated at the first close.

It is genuinely possible and, in strong market cycles, has happened in veterinary platforms — it is not a certainty.

Sources

Industry M&A research and valuation data

Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com. https://www.capstonepartners.com/insights/article-pet-sector-ma-update/
Colonnade Advisors. “Rollover Equity: A Second Bite at the Apple.” coladv.com. https://coladv.com/recent_updates/rollover-equity/
Colonnade Advisors. “009: Second Bite at the Apple — Aligning Interests through Rollover Equity.” coladv.com. https://coladv.com/podcasts/009/
GlobalPETS. “Deal or no deal? Pet industry M&A in 2026.” globalpetindustry.com. https://globalpetindustry.com/article/deal-or-no-deal-pet-industry-ma-in-2026/

Rollover equity structure and tax treatment